A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-11) →
What happened
Komipharm International reported consolidated results for FY2025: revenue of US$36.2M (−10.74% year on year), operating profit of US$1.54M (−64.03% year on year) and a net loss of US$5.13M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$36.2M |
|---|---|
| Revenue vs a year earlier | −10.74% |
| Operating profit | US$1.54M |
| Net income | −US$5.13M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-20, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260220901105 → open original filing |
Versions of this filing
- 2026-02-20Original (this page)
- 2026-03-11Amendment 1
Source: DART. Information only, not investment advice.